Eli Lilly shares fell 2.6%, dragging healthcare sector down 0.5%. Q3 revenue was up 27% to $11.4bn on Mounjaro and Zepbound demand. Adjusted EPS rose to $1.89. FY25 EPS guidance $22.50 to $23.50
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
